Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer

Molecular Therapy Nucleic Acids

Volumn 4, Issue 3, 2015, Pages e231-

  Hiraki, Masayuki ^a   Nishimura, Junichi ^a   Takahashi, Hidekazu ^a   Wu, Xin ^a   Takahashi, Yusuke ^a   Miyo, Masaaki ^a   Nishida, Naohiro ^a   Uemura, Mamoru ^a   Hata, Taishi ^a   Takemasa, Ichiro ^a   Mizushima, Tsunekazu ^a   Soh, Jae Won ^b   Doki, Yuichiro ^a   Mori, Masaki ^a   Yamamoto, Hirofumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inha University   (South Korea)

Author keywords

AKT; Colorectal cancer; KRAS; MicroRNA; MiR 4689

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 296 5P; MICRORNA 3619 3P; MICRORNA 4270; MICRORNA 4442; MICRORNA 4685 3P; MICRORNA 4689; MICRORNA 4731 3P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; EMBRYO; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROBLAST; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; TUMOR GROWTH; UREA NITROGEN BLOOD LEVEL;

EID: 84958534027     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.5     Document Type: Article

References (48)

1. Karapetis, CS, Khambata-Ford, S, Jonker, DJ, O'Callaghan, CJ, Tu, D, Tebbutt, NC et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
2. Van Cutsem, E, Köhne, CH, Hitre, E, Zaluski, J, Chang Chien, CR, Makhson, A et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360: 1408-1417.
3. Bokemeyer, C, Bondarenko, I, Makhson, A, Hartmann, JT, Aparicio, J, de Braud, F et al (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671
4. De Roock, W, Jonker, DJ, Di Nicolantonio, F, Sartore-Bianchi, A, Tu, D, Siena, S et al. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304 1812-1820.
5. Yarden, Y and Sliwkowski, MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
6. Scaltriti, M and Baselga, J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272.
7. Lièvre, A, Bachet, JB, Le Corre, D, Boige, V, Landi, B, Emile, JF et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
8. Bardelli, A and Siena, S (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261
9. Giehl, K (2005). Oncogenic Ras in tumour progression and metastasis. Biol Chem 386: 193-205.
10. Campbell, SL, Khosravi-Far, R, Rossman, KL, Clark, GJ and Der, CJ (1998). Increasing complexity of Ras signaling. Oncogene 17: 1395-1413.
11. Lorusso, PM, Adjei, AA, Varterasian, M, Gadgeel, S, Reid, J, Mitchell, DY et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281-5293.
12. Menon, SS, Whitfield, LR, Sadis, S, Meyer, MB, Leopold, J, Lorusso, PM et al. (2005). Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol 23: 3066.
13. Lim, HY Yen, C-J, Tak, W-Y, Heo, J, Choi, HJ, Lin, CY et al. (2012). A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 30: 4103.
14. Macarulla, T Tabernero, J, Cervantes, A, Roselló, S, Van Cutsem, E, Tejpar, S et al. (2012). Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369b) as second-line treatment for kras mutated metastatic colorectal cancer. Ann Oncol 23: PD-0024.
15. Calin, GA and Croce, CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
16. Bartel, DP (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
17. Bartel, DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297
18. Bartel, DP and Chen, CZ (2004). Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5: 396-400.
19. ∗ microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30: 953-959.
20. Pagliuca, A, Valvo, C, Fabrizi, E, di Martino, S, Biffoni, M, Runci, D et al. (2013). Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32: 4806-4813.
21. Liao, WT, Ye, YP Zhang, NJ, Li, TT, Wang, SY, Cui, YM et al. (2014). MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol 232: 415-427.
22. Didiano, D and Hobert, O (2006). Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 13: 849-851
23. Garcia, DM, Baek, D, Shin, C, Bell, GW, Grimson, A and Bartel, DP (2011). Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 18: 1139-1146.
24. Cheng, Z, Garvin, D, Paguio, A, Stecha, P, Wood, K and Fan, F (2010). Luciferase Reporter Assay System for Deciphering GPCR Pathways. Curr Chem Genomics 4: 84-91.
25. Ling, H, Fabbri, M and Calin, GA (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865.
26. Schwarzenbach, H, Nishida, N, Calin, GA and Pantel, K (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11: 145-156.
27. Farazi, TA, Ten Hoeve, JJ, Brown, M, Mihailovic, A, Horlings, HM, van de Vijver, MJ et al. (2014). Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol 15: R9.
28. Chowdhury, EH, Maruyama, A, Kano, A, Nagaoka, M, Kotaka, M, Hirose, S et al. (2006). pH-sensing nano-crystals of carbonate apatite: effects on intracellular delivery and release of DNA for efficient expression into mammalian cells. Gene 376: 87-94.
29. Hossain, S, Yamamoto, H, Chowdhury, EH, Wu, X, Hirose, H, Haque, A et al. (2013). Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor. PLoS One 8: e60428.
30. Takeyama, H, Yamamoto, H, Yamashita, S, Wu, X, Takahashi, H, Nishimura, J et al. (2014). Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther 13: 976-985.
31. Migliardi, G, Sassi, F, Torti, D, Galimi, F, Zanella, ER, Buscarino, M et al. (2012). Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18: 2515-2525.
32. Misale, S, Yaeger, R, Hobor, S, Scala, E, Janakiraman, M, Liska, D et al. (2012). Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
33. Lee, J, Lee, I, Han, B, Park, JO, Jang, J, Park, C et al. (2011). Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103: 674-688.
34. Zhang, J, Guo, H, Qian, G, Ge, S, Ji, H, Hu, X et al. (2010). MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer 9: 211.
35. Hoeflich, KP, O'Brien, C, Boyd, Z, Cavet, G, Guerrero, S, Jung, K et al. (2009). In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664.
36. Williams, TM, Flecha, AR, Keller, P, Ram, A, Karnak, D, Galbán, S et al. (2012). Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther 11: 1193-1202.
37. Zhong, H, Sanchez, C, Spitrzer, D, Plambeck-Suess, S, Gibbs, J, Hawkins, WG et al. (2013). Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One 8: e77243.
38. Wee, S, Jagani, Z, Xiang, KX, Loo, A, Dorsch, M, Yao, YM et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293.
39. Singh, A, Sweeney, MF, Yu, M, Burger, A, Greninger, P, Benes, C et al. (2012). TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148: 639-650.
40. Kota, J, Chivukula, RR, O'Donnell, KA, Wentzel, EA, Montgomery, CL, Hwang, HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
41. Wiggins, JF, Ruffino, L, Kelnar, K, Omotola, M, Patrawala, L, Brown, D et al. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
42. Janssen, HL, Reesink, HW, Lawitz, EJ, Zeuzem, S, Rodriguez-Torres, M, Patel, K et al. (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685-1694.
43. Zhou, J, Shum, KT, Burnett, JC and Rossi, JJ (2013). Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) 6: 85-107.
44. Decuzzi, P, Causa, F, Ferrari, M and Netti, PA (2006). The effective dispersion of nanovectors within the tumor microvasculature. Ann Biomed Eng 34: 633-641.
45. Ebi, H, Corcoran, RB, Singh, A, Chen, Z, Song, Y, Lifshits, E et al. (2011). Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 121: 4311-4321.
46. Schmittgen, TD, Jiang, J, Liu, Q and Yang, L (2004). A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 32: e43.
47. Yamamoto, H, Kondo, M, Nakamori, S, Nagano, H, Wakasa, K, Sugita, Y et al. (2003). JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology 125: 556-571.
48. Hossain, S, Stanislaus, A, Chua, MJ, Tada, S, Tagawa, Y, Chowdhury, EH et al. (2010). Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 147: 101-108.